Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M4936 | Omarigliptin | Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor with IC50 of 1.6 nM; highly selective over all proteases tested (IC50 > 67 _mu_M). |
| M1967 | Sitagliptin phosphate monohydrate | Sitagliptin phosphate (MK-0431) is a potent inhibitor of dipeptidyl peptidase-4 (DPP-4) with IC50 of 19 nM. |
| M5965 | Sitagliptin | Sitagliptin (MK 0431) is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts. |
| M3119 | Vildagliptin | Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity. |
| M2341 | Trelagliptin | Trelagliptin (SYR-472) is a novel once-weekly oral DPP-4 inhibitor for type 2 diabetes. |
| M8882 | Trelagliptin succinate | Trelagliptin(SYR-472) succinate is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). |
| M2814 | Linagliptin | Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. |
| M28256 | P32/98 | P32/98 a potent inhibitor of dipeptidyl peptidase IV with a Ki value of 130 nM. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model. |
| M28160 | Fotagliptin | Fotagliptin is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC50=2.27 nM). Fotagliptin displays great security in rat and dog. Fotagliptin can be used for Type 2 diabetes mellitus research. |
| M27970 | Evogliptin tartrate | Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation. |
| M27969 | Evogliptin | Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation. |
| M20841 | Gemigliptin | Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α. |
| M17954 | (1 (10)E,2R*,5R*)-2-methoxy-5-acetoxyfuranogermacr-1 (10)-en-6-one | （1（10）E,2R*,5R*）-2-methoxy-5-acetoxyfuranogermacr-1（10）-en-6-one |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
